I am a Clinical Portfolio Leader in the Inflammation and Immunology Research Unit with over 25 years of experience in drug discovery and development at Pfizer. I began my career at Pfizer in the oncology discovery labs in Groton. I had roles of increasing responsibility including leadership of Discovery biology efforts for oncology, immunology and antibacterial research and Team leader for oncology assets in clinical development.
In my current role, I lead the development teams that are responsible for milestones from First-in-Human through Proof-of-Concept for both biologic and small molecule approaches for Inflammation and Immunology assets. I am tremendously proud of my teams’ achievements, including most recently, the JAK1 asset that achieved Proof-of-Concept in atopic dermatitis including a Phase 3 start in 2017.
I earned my BS degree in Biochemistry from the University of Vermont and my Ph.D in Molecular Pharmacology from the University of Michigan.
The teams who work in the early development space are accountable for milestones from First-in-Human through Proof-of-Concept. Team members bring valuable perspectives from their lines and work tirelessly to ensure we assemble the most efficient strategies to test our scientific hypotheses in humans.
These teams assemble development plans that include precision medicine approaches that allow us to quantitate the pharmacodynamic activity of our compounds and to understand the patient populations that may have the best response to our drug. We explore a variety of disease areas in the Inflammation and Immunology RU that includes Systemic Lupus Erythematosus, lupus nephritis, atopic dermatitis, rheumatoid arthritis, to name a few.
The culture of the teams is really important to me – I want team members to be empowered to challenge our assumptions, raise issues and concerns, and to take risks as well as to be efficient with our spending – this is so important to ensure we bring the best plans forward.
- Increased Serum Enzyme Levels Associated with Kupffer Cells Reduction with No Signs of Hepatic or Skeletal Muscle Injury. American Journal of Pathology 179:240-7, 2011. Radi, ZA, Koza-Taylor, PH, Bell RR, Obert L, Giovanelli RP, Runnels HA, Beebe JS, Lawton MP, Sadis, S https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3123844/
- Anti-IL21 receptor monoclonal antibody (ATR-107): Safety, pharmacokinetics, and pharmacodynamic evaluation in healthy volunteers: a phase 1, first-in-human study. J Clin Pharm 54(1): 14-22, 2014. Hua F, Comer GM, Stockert L, Jin B, Nowak J, Pleasic-WilliamsS, Wunderlich D, Cheng J, Beebe JS
- Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial. Ann Rheum Dis76: 534, 2017 Published Online First [Sept 26, 2016] doi:10.1136/annrheumdis-2016-209668. Wallace DJ, Strand V, Merrill JT, Popa S, Spindler, AJ, Eimon A, Petri M, Smolen JS, Wajdula J, Christensen J, Li C, Diehl A, Vincent MS, Beebe J, Healey P, Sridharan https://www.ncbi.nlm.nih.gov/pubmed/27672124
- Randomized trial and open-label extension study of an anti-interleukin-6 antibody in Crohn’s disease (ANDANTE I and II) Gut Published online First [Dec 15, 2017] doi:1136/gutjnl-2017-314562. Danese S, Vermeire S, Hellstern P, Panaccione R, Rogler G, Fraser G, Kohn A, Desreumaux, P, Leong RW, Comer GM, Cataldi F, Banerjee A, Maguire MK, Li C, Rath N, Beebe J, Schreiber S https://www.ncbi.nlm.nih.gov/pubmed/29247068
- PF-04965842, a JAK1 inhibitor, for treatment of atopic dermatitis: a 12-week, randomised, double-blind, placebo-controlled phase 2 clinical trial. Late-breaker abstract at 2017 EADV conference, Geneva. Gooderham M, Forman S, Bissonnette R, Beebe J, Zhang W, Banfield C, Zhu L, Papacharalambus J, Vincent M, Peeva E
University of Vermont, Burlington, Biochemistry B.S., 1984
University of Michigan, Ann Arbor, Molecular Pharmacology, Ph.D., 1989
“I joined Pfizer because I was so impressed with how the scientists worked together in multidisciplinary teams and are united in a common goal of bringing new medicines to patients. I have stayed at Pfizer because I have the privilege of working with so many exceptional colleagues and so many opportunities to learn. And because I am fully committed and all-in on our mission to develop new innovative medicines.”